Serum SP70 is a sensitive predictor of chemotherapy response in patients with advanced nonsmall cell lung cancer

Abstract SP70 is a novel tumor biomarker in patients with nonsmall cell lung cancer (NSCLC). However, its role as a marker for predicting the response to chemotherapy for patients with advanced NSCLC has not been investigated. A total of 152 patients were enrolled. Serum SP70, carcinoembryonic antig...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Jingping Liu, Wei Zhang, Min Gu, Yazhou Ji, Lu Yang, Xiangjun Cheng, Xuelian Xiao, Jian Xu, Chunrong Gu, Jiexin Zhang, Shichang Zhang, Dan Chen, Shiyang Pan
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Wiley 2018-07-01
Sarja:	Cancer Medicine
Aiheet:	clinical efficacy nonsmall cell lung cancer progression‐free survival SP70 tumor markers
Linkit:	https://doi.org/10.1002/cam4.1555
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!